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Abstract 
Background: The renin‑angiotensin system (RAS) has been implicated in atherosclerotic lesions and progression to 
chronic kidney diseases. We examined regulatory roles of angiotensin‑converting enzyme 2 (ACE2) in the apolipopro‑
tein E (ApoE) knockout (KO) kidneys.
Methods: The 3‑month‑old wild‑type, ApoEKO, ACE2KO and ApoE/ACE2 double‑KO (DKO) mice in a C57BL/6 
background were used. The ApoEKO mice were randomized to daily deliver either Ang II (1.5 mg/kg) and/or human 
recombinant ACE2 (rhACE2; 2 mg/kg) for 2 weeks. We examined changes in pro‑inflammatory cytokines, renal ultras‑
tructure, and pathological signaling in mouse kidneys.
Results: Downregulation of ACE2 and nephrin levels was observed in ApoEKO kidneys. Genetic ACE2 deletion 
resulted in modest elevations in systolic blood pressure levels and Ang II type 1 receptor expression and reduced 
nephrin expression in kidneys of the ApoE/ACE2 DKO mice with a decrease in renal Ang‑(1‑7) levels. These changes 
were linked with marked increases in renal superoxide generation, NADPH oxidase (NOX) 4 and proinflammatory 
factors levels, including interleukin (IL)‑1beta, IL‑6, IL‑17A, RANTES, ICAM‑1, Tumor necrosis factor‑alpha (TNF‑alpha) 
and TNFRSF1A. Renal dysfunction and ultrastructure injury were aggravated in the ApoE/ACE2 DKO mice and Ang II‑
infused ApoEKO mice with increased plasma levels of creatinine, blood urea nitrogen and enhanced levels of Ang II in 
plasma and kidneys. The Ang II‑mediated reductions of renal ACE2 and nephrin levels in ApoEKO mice were remark‑
ably rescued by rhACE2 supplementation, along with augmentation of renal Ang‑(1‑7) levels. More importantly, 
rhACE2 treatment significantly reversed Ang II‑induced renal inflammation, superoxide generation, kidney dysfunc‑
tion and adverse renal injury in ApoEKO mice with suppression of the NOX4 and TNF‑alpha‑TNFRSF1A signaling. 
However, rhACE2 had no effect on renal NOX2 and TNFRSF1B expression and circulating lipid levels.
Conclusions: ACE2 deficiency exacerbates kidney inflammation, oxidative stress and adverse renal injury in the 
ApoE‑mutant mice through modulation of the nephrin, NOX4 and TNF‑alpha‑TNFRSF1A signaling. While rhACE2 
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supplementation alleviates inflammation, renal dysfunction and glomerulus injury in the ApoE‑mutant mice associ‑
ated with upregulations of Ang‑(1‑7) levels and nephrin expression and suppression of the TNF‑alpha‑TNFRSF1A 
signaling. Strategies aimed at enhancing the ACE2/Ang‑(1‑7) actions may have important therapeutic potential for 
atherosclerotic renal injury and kidney diseases.
Keywords: Angiotensin‑converting enzyme 2, Apolipoprotein E, Angiotensin II, Inflammation, Nephrin, Renal injury
the atherosclerosis-prone ApoEKO mice. To this aim, we 
evaluated the influences of ACE2 deficiency and Ang II 
infusion on renal inflammatory factors, reactive oxygen 
species (ROS) production and ultrastructural changes in 
the ApoEKO kidneys. We also examined the regulatory 
effects of human recombinant ACE2 (rhACE2) on the 
Ang II-mediated above-mentioned outcomes.
Methods
Animal Preparation
The 12-week-old male ApoEKO, ACE2KO and the ApoE/
ACE2 double KO (DKO) mice in a C57BL/6 background 
were used in these experiments as previously described 
[8, 14, 18]. The ApoEKO mice were randomized to 
deliver either Ang II (1.5 mg.kg−1 day−1) or saline (vehi-
cle) with an osmotic minipump (model 1002, Alzet Corp, 
Palo Alto, CA, USA) for 2 weeks as previously described 
[9, 14, 18]. In a separate experiment, the saline (Vehi-
cle)- or Ang II-infused ApoEKO mice were daily treated 
with placebo or rhACE2 (2  mg/kg, intraperitoneal) as 
before [8, 9]. Throughout the study mice were housed in 
pathogen-free conditions and given access to standard 
mouse chow and water ad  libitum. Systolic blood pres-
sure (SBP) levels of mice were measured non-invasively 
using the tail-cuff method. All plasma determinations 
were performed using a Beckman CX7 chemistry ana-
lyzer for blood urea nitrogen (BUN), creatinine (Cr), total 
cholesterol (CHO) and triglycerides (TG). Ang II levels in 
plasma and renal cortex were measured by radio-immu-
noassay as previously described [8]. Mice were anesthe-
tized with ketamine (80 mg/kg) and xylaxine (10 mg/kg). 
All experiments were approved and performed in accord-
ance to institutional guidelines for Canadian Council on 
Animal Care, the Animal Research Ethics Committee at 
Shanghai Jiao Tong University School of Medicine and 
the Guide for the Care and the Guide for the Care and 
Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 
1996).
Transmission electron microscope analysis, 
immunohistological and immuno‑fluorescence staining
For transmission electron microscope (TEM) analysis, 
samples of mouse renal cortex tissues were immediately 
cut into small pieces and prefixed in 2.5% glutaraldehyde 
Background
Atherosclerosis is considered one of the major risk fac-
tors for renal injury and the progression of chronic kid-
ney diseases (CKD) to end-stage renal diseases (ESRD), 
which is costly and important clinical event with substan-
tial morbidity [1–4]. Patients with CKD have a substan-
tially increased risk for atherosclerotic cardiovascular 
death and total mortality and loss of renal parenchyma 
accelerates atherosclerosis in animal models [3, 5, 6], 
indicating the interplay between atherosclerosis and 
kidney injury. Activation of the renin-angiotensin sys-
tem (RAS) has an enhanced susceptibility to atheroscle-
rotic lesions, renal inflammation and ESRD [3, 7–11]. 
Angiotensin (Ang) II plays a pivotal role in perpetuat-
ing glomerular injury in kidney via the modulation of 
nephrin signaling, the integrity of which is crucial for 
the glomerular filtration barrier [12]. Ang II has direct 
proatherosclerotic and proinflammatory actions, whereas 
pharmacological blockade of the RAS has anti-athero-
sclerotic and antiinflammatory effects, additional and 
independent of systemic blood pressure [7, 13–15]. The 
pathophysiologic mechanisms underlying the accelerated 
progression of renal dysfunction in atherosclerosis status 
and the interactions between the RAS and nephrin sign-
aling in atherosclerotic kidney injury remain to be fully 
clarified.
Angiotensin-converting enzyme 2 (ACE2) is a negative 
regulator of the RAS, catalyzing the conversion of Ang II 
to the beneficial heptapeptide Ang-(1-7), thereby coun-
terbalancing the ACE/Ang II actions [16–18]. Genetic 
ACE2 deficiency accentuates vascular inflammation and 
atherosclerosis in the apolipoprotein E (ApoE) knockout 
(KO) mouse with larger vascular lesions in aortic athero-
sclerotic plaques [7, 11, 19]. Moreover, ACE2-deficient 
mice are more susceptible to renal inflammation, fibro-
sis and kidney injury [8, 20]. In contrast, our previous 
studies demonstrated that ACE2 overexpression attenu-
ates atherosclerosis in the ApoEKO mice [21] and pre-
vents Ang II-mediated tubulointerstitial fibrosis and 
renal dysfunction in hypertensive mice [8–10], suggest-
ing beneficial effects of ACE2 on the kidneys. However, 
the exact roles and mechanisms of ACE2 in atheroscle-
rotic renal injury are poorly understood. In this study, 
we hypothesized that ACE2 is a negative regulator of 
kidney inflammation, oxidative stress and renal injury in 
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as previously described [18]. The renal ultrastructure of 
mouse was observed on a PHILIPS CM-120 transmission 
electron-microscope (Holland) with ×4200 and ×7400 
magnifications.  Five  micrometer thick formalin fixed 
paraffin embedded sections were used for the immuno-
histological staining for AT1 receptor and the immu-
nofluorescence staining for nephrin in the renal cortex 
of ApoEKO and ApoE/ACE2 DKO mice as previously 
described [18].
Quantitative real‑time PCR analysis
The mRNA levels were evaluated by quantitative real-
time reverse transcription PCR as before [8, 16]. Total 
RNA was extracted from renal cortex tissues using 
TRIzol reagent (Invitrogen) and the cDNA was synthe-
sized using the PrimeScript RT reagent kit (TAKARA). 
Sequences of the forward primers and reverse prim-
ers are listed in Table 1. The quantitative real-time PCR 
was run in 384-well plates using a SYBR Premix ExTaq II 
(TAKARA). Relative mRNA levels were quantified using 
ABI 7900T Real Time System SDS 2.3 software (Applied. 
Biosystems, Carlsbad, CA, USA). GAPDH was used as an 
endogenous control. All samples were run in triplicates.
Cytokine protein arrays and western blotting analysis
To further implore the effects of ACE2 deficiency on 
inflammation in ApoEKO mice, we studied the renal 
levels of pro-inflammatory cytokines/chemokines by 
using the RayBio® C-Series Mouse Cytokine Antibody 
Array 1000 (Array C3 and C4; RayBiotech Inc, Norcross, 
GA, USA; http://www.raybiotech.com/c-series-mouse-
cytokine-array-c1000-2.html). The cytokine protein arrays 
were performed according to manufacturer’s instructions 
as previously described [22]. Biotin-conjugated immu-
noglobulin G served as a positive control at six spots. 
For each sample spot, the ratio of relative expression was 
established after subtraction of the background intensity 
and comparison with the positive spots available in the 
membrane. The proteins from renal cortex tissues were 
measured by Western blotting analysis as previously 
described [9, 17]. The primary antibody against ACE2 (90 
kD), nephrin (185 kD), tumor necrosis factor-α (TNF-α; 
17 kD), TNFRSF1A (55 kD), IL-17A (17 kD), AT1 (41 kD) 
and β-actin (45  kD) were obtained from R&D Systems 
(Minneapolis, MN), Abcam Inc. (Cambridge, MA,USA), 
Cell Signaling Technology (Beverly, MA), and Santa 
Cruz Biotechnology (Santa Cruz, CA, USA), respectively. 
β-actin was used as an endogenous control.
Dihydroethidium fluorescence and measurement 
of NADPH oxidase activity
To evaluate superoxide production in kidneys of mice, 
we performed the oxidative fluorescent dye dihydroeth-
idium (DHE) staining as previously described [8, 18]. 
Briefly, fresh frozen tissue sections (20  μm) for mouse 
kidneys were incubated at 37°C for 30  min with DHE 
(20 μM) in hanks balanced salt solution. For a separated 
experiment, kidney tissue sections from the ApoEKO 
mice with Ang II pumps were incubated with polyethyl-
ene glycol-conjugated superoxide dismutase (PEG-SOD; 
500 U/mL) at 37°C for 30 min prior to 30-min exposure 
of DHE (20 μM). Fluorescent images were observed with 
an Olympus Fluoview laser-scanning confocal micro-
scope mounted on an Olympus microscope selected with 
CY3 (red) channel. The activities of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase in kidney 
issues of mice were measured by the lucigenin-enhanced 
chemiluminescence assay as previously reported [8, 
18]. The kidney homogenates (100  μg total proteins) 
were collected in 100  μl of PBS mixture with protease 
and phosphatase inhibitor (Sigma-Aldrich) and then 
centrifuged at 1,000 g for 10 min. NADPH (1 mM) and 
lucigenin (50  μM) were added to the supernatants for 
NADPH oxidase activities assay at 37°C. The diphenylene 
iodonium (DPI, 10  μM) was used as a selective inhibi-
tor of NADPH oxidase. The light emission over a 3-min 
period was averaged for each sample.
Table 1 Primers sequences for real-time PCR analysis
TNFα tumor necrosis factor-α, TNFRSF1A tumor necrosis factor receptor 
superfamily member 1A, TNFRSF1B tumor necrosis factor receptor superfamily 
member 1B, IL-1β interleukin-1β, IL-6 interleukin-6, IL-17A interleukin-17A, NOX2 
NADPH oxidase 2, NOX4 NADPH oxidase 4, GAPDH glyceraldehyde-3-phosphate 
dehydrogenase.
Genes Primers Sequences (5′–3′)
TNF‑α Forward primer 5′‑ACAAGGCTGCCCCGACTAC‑3′
Reverse primer 5′‑TCTCCTGGTATGAGATAGCA‑3′
TNFRSF1A Forward primer 5′‑CCTCCTCAGTGGGTTTCT‑3′
Reverse primer 5′‑CGCCTTTCTATGCTTGTCC‑3′
TNFRSF1B Forward primer 5′‑TGATGACATCGGTTGAAAG‑3′
Reverse primer 5′‑TGATGACATCGGTTGAAAG‑3′
IL‑1β Forward primer 5′‑AACCTGCTGGTGTGTGACGTTC‑3′
Reverse primer 5′‑CAGCACGAGGCTTTTTTGTTGT‑3′
IL‑6 Forward primer 5′‑ACAACCACGGCCTTCCCTACTT‑3′
Reverse primer 5′‑CACGATTTCCCAGAGAACATGTG‑3′
IL‑17A Forward primer 5′‑GGACTCTCCACCGCAATGA‑3′
Reverse primer 5′‑GTTTCTTAGGGGTCAGCCG‑3′
NOX2 Forward primer 5′‑TTGTGGGAGACTGGACGGA‑3′
Reverse primer 5′‑ATGGAGGCAAAGGGCGTGA‑3′
NOX4 Forward primer 5′‑TCTCCATTGCCCCAGTGTA‑3′
Reverse primer 5′‑AGGCAGTAGCAAATCCCG‑3′
Nephrin Forward primer 5′‑CCCATTCAAAGGCTCCGCT‑3′
Reverse primer 5′‑ACTGCCCGCACTTGCTCTC‑3′
GAPDH Forward primer 5′‑TGCGACTTCAACAGCAACTC‑3′
Reverse primer 5′‑ATGTAGGCCATGAGGTCCAC‑3′
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Statistical analysis
All data are shown as mean ± SEM. All statistical analy-
ses were performed with SPSS software (version 16.0) 
either by Student’s t test for comparison between two 
groups or by ANOVA followed by the Student-Neuman–
Keuls test for multiple-comparison testing as appro-
priate. A value of P  <  0.05 was considered to indicate 
statistical significance.
Results
Deletion of ACE2 facilitates renal dysfunction in the ApoE/
ACE2 DKO mice with decreased nephrin levels
Kidneys obtained from the ApoEKO mice showed 
marked decreases in ACE2 protein (Fig. 1) and nephrin 
levels (Fig. 2) compared with the kidneys from WT con-
trols. There were no changes in SBP, Ang II and Ang-(1-
7) levels between the WT and ApoEKO mice (Table  2; 
Fig. 1). As shown in Table 2, plasma total CHO and TG 
concentrations were elevated in both the ApoEKO and 
ApoE/ACE2 DKO mice when compared to WT control 
mice. However, ACE2 deficiency had no effect on circu-
lating lipid levels in the ACE2KO mice and ApoE/ACE2 
DKO mice. In addition, ACE2 deficiency led to marked 
down-regulations in nephrin mRNA and protein levels 
in the single ACE2KO and ApoE/ACE2 DKO kidneys 
(Fig. 2). Intriguingly, ACE2 deficiency resulted in modest 
elevations in SBP levels and increased renal Ang II levels 
in both the single ACE2-mutant and ApoE/ACE2 dou-
ble-mutant mice with accompanying decreases in renal 
Ang-(1-7) levels and the Ang-(1-7)/Ang II ratio (Table 2; 
Fig. 1). These changes were associated with exacerbation 
of renal dysfunction with enhanced plasma levels of Cr 
and BUN (Table 2). Clearly, these observations revealed 
detrimental effect of ACE2 deficiency on nephrin 
signaling and renal dysfunction is dependent on the bal-
ance between Ang II and Ang-(1-7) levels.
Deletion of ACE2 facilitates renal inflammation 
and oxidative stress in the ApoE‑deficient mice 
via activation of the TNF‑α‑TNFRSF1A and NOX4 signaling
Activation of the RAS has been linked to inflammation 
and oxidative stress, key determinants of adverse renal 
injury [8, 20]. We evaluated the effects of ACE2 deficiency 
on renal inflammation and ROS levels in the ApoE/ACE2 
DKO mice. The Western blot analysis and representative 
immunohistological staining images showed that there 
was upregulation of AT1 receptor levels in the ApoE/
ACE2 DKO kidneys compared with the ApoEKO kidneys 
(Fig.  3). These changes were linked with downregulated 
levels of anti-inflammatory cytokine interleukin 4 (IL4) 
and increased levels of pro-inflammatory cytokines/
chemokines and adhesion molecules in the ApoE/ACE2 
DKO kidneys by cytokine protein arrays, including 
TNF-α, CD30L, RANTES (CCL5), intercellular adhe-
sion molecule 1 (ICAM-1), IL-1β, IL-3, IL-6, IL-13, and 
IL-17A (Fig.  3; Table  3). Furthermore, ACE2 deficiency 
resulted in marked increases in TNF-α related signal-
ing such as Fas Ligand (TNFSF6), GITR (TNFRSF18), 
Osteoprotegerin (TNFRSF11B), TRANCE (TNFSF11) 
and TNFRSF1A (Fig.  3; Table  3). However, there were 
no alterations in renal levels of TNFRSF1B, TROY 
(TNFRSF19), CD30, IL-1α, IL-2, IL-5, IL-7, IL-9, IL-10, 
IL-15, IL-17RB and VCAM-1 between the ApoEKO mice 
and ApoE/ACE2 DKO mice (Fig.  3; Table  3). Real-time 
PCR and Western blot analyses revealed that there were 
significant increases in expression of TNF-α, TNFRSF1A, 
IL-1β, IL-6, and IL-17A in the ApoEKO kidneys com-
pared with WT control kidneys (Fig.  4). Moreover, 
Fig. 1 Renal ACE2, Ang II and Ang‑(1‑7) levels in the mice. a Representative Western blot analysis showing ACE2 protein levels in the mice kidneys. 
β‑actin was used as an endogenous control. b, c The Ang II and Ang‑(1‑7) levels (b) and the ratio of Ang‑(1‑7)/Ang II (c) in the kidney cortex of 
mice. AU arbitrary units, WT wildtype, ApoE apolipoprotein E, KO knockout, DKO the ApoE/ACE2 double knockout, Ang II angiotensin II. n = 5–6. 
*P < 0.05;**P < 0.01 compared with WT group; #P < 0.05, compared with ApoEKO group.
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Fig. 2 Loss of ACE2 resulted in downregulation of renal nephrin levels in the ApoE/ACE2 DKO mice. The real‑time PCR and Western blot analyses 
for nephrin mRNA (a), nephrin protein (b) and representative nephrin immunofluorescence images (c, d) showing downregulation of nephrin levels 
in the ApoE/ACE2 DKO kidneys compared with the ApoEKO kidneys. n = 5–6; β‑actin or GAPDH was used as an endogenous control. In the immu‑
nofluorescence images, the red color represents nephrin and blue color represents DAPI stained nuclei. RE relative expression, AU arbitrary units, WTC 
wild‑type control, ApoE Apolipoprotein E, KO knockout, DKO the ApoE/ACE2 double knockout mice. *P < 0.05; **P < 0.01 compared with WT control 
group; #P < 0.05 compared with ApoEKO group.
Table 2 The general data in mice
SBP systolic blood pressure, BW body weight, BUN blood urea nitrogen, Cr creatinine, TG triacylglycerol, CHO cholesterol, Ang II angiotensin II, KO knockout, WTC wild-
type control mice, ApoE apolipoprotein E, DKO ApoE/ACE2 double knockout mice, ACE2 angiotensin-converting enzyme 2, rhACE2 recombinant human ACE2.
Results are presented as mean ± SEM. * P < 0.05, ** P < 0.01 compared with WTC group; # P < 0.05, ## P < 0.01 compared with ApoEKO control group; φ P < 0.05 
compared with ApoEKO + Ang II group.






n 8 7 8 7 7 6 5
SBP (mm Hg) 100.8 ± 3.5 103.1 ± 2.4 118.3 ± 3.1** 124.5 ± 3.3**# 104.5 ± 3.0 153.2 ± 4.2## 127.2 ± 3.1φ
BW (g) 25.1 ± 1.2 25.9 ± 1.0 24.7 ± 0.8 23.5 ± 1.2 26.1 ± 1.1 24.6 ± 1.4 25.3 ± 1.5
BUN (mmol/L) 6.4 ± 0.3 9.3 ± 0.4* 9.4 ± 0.7* 13.9 ± 0.9**## 8.9 ± 0.6 15.6 ± 0.7## 10.5 ± 0.6φ
Cr (μmol/L) 11.1 ± 0.8 18.4 ± 1.5* 19.8 ± 1.9* 40.4 ± 4.0**## 10.3 ± 1.0# 52.4 ± 7.2## 25.8 ± 1.7φ
TG (mmol/L) 0.59 ± 0.05 1.14 ± 0.07* 0.73 ± 0.08 1.23 ± 0.13* 1.06 ± 0.11 1.23 ± 0.16 1.15 ± 0.13
CHO (mmol/L) 1.48 ± 0.11 6.46 ± 0.34** 1.61 ± 0.15 7.31 ± 0.60** 6.4 ± 0.4 8.57 ± 0.43 8.25 ± 0.5
Plasma Ang II (pg/mL) 38.6 ± 1.8 43.5 ± 2.1 69.0 ± 3.8* 75.3 ± 4.6**# 40.9 ± 2.1 302.9 ± 15.9## 172.2 ± 14.4φ
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deletion of ACE2 resulted in activation of the TNF-α-
TNFRSF1A signaling and elevated levels of IL-1β, IL-6 
and IL-17A in both the ACE2KO and ApoE/ACE2 DKO 
kidneys, without affecting the expression of TNFRSF1B 
(Fig.  4). Kidneys obtained from the ApoEKO mice 
showed elevated superoxide production (Fig. 5c, d) com-
pared with the kidneys from WT controls. Of note, ACE2 
deficiency led to increases in renal oxidative stress lev-
els and NADPH oxidase activity (Fig. 5d) and enhanced 
renal expression of oxidative stress-inducible gene 
NADPH oxidase 4 (NOX4; Fig. 5b) not only in the single 
ACE2 mutant mice but also in mice carrying mutations 
in both ACE2 and ApoE gene (n = 5–6, P < 0.05, respec-
tively). However, deletion of ACE2 had no effects on the 
renal NOX2 levels (Fig. 5a).
Treatment with rhACE2 prevents renal dysfunction 
and inflammation in the ApoEKO mice in response to Ang II
Given that ACE2 deficiency is functionally relevant 
in worsening the impaired kidney phenotypes of the 
ApoEKO mice, we speculated that rhACE2 supplementa-
tion should rescue Ang II-mediated pathological actions 
in kidneys. In response to Ang II, the renal ACE2 pro-
tein and renal Ang-(1-7)/Ang II ratio were markedly 
Fig. 3 ACE2 deficiency resulted in elevated AT1 receptor levels and renal inflammation in ApoE/ACE2 DKO kidneys. a, b The Western blot analysis 
for AT1 receptor protein (a) and representative immunohistological staining images for AT1 receptor (b) showing upregulation of AT1 receptor 
levels in the ApoE/ACE2 DKO kidneys compared with the ApoEKO kidneys. n = 5; β‑actin was used as an endogenous control. c, d Quantification 
of cytokines in kidney tissues of the ApoEKO and ApoE/ACE2 DKO mice by the mouse cytokine‑specific antibody arrays (array C3: upper; array C4: 
bottom). n = 3 for each group. Please see the related description in Table 3. AU arbitrary units, ApoE apolipoprotein E, KO knockout, DKO the ApoE/
ACE2 double knockout. **P < 0.01 compared with ApoEKO group.
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decreased in the ApoEKO mice with elevated Ang II 
levels in kidneys and plasma (Table 2; Fig. 6). There was 
no significant change in Ang-(1-7) levels between the 
vehicle-treated ApoEKO and Ang II-treated ApoEKO 
mice (Fig.  6). Continuous infusion of Ang II resulted in 
a predicted pressor response, a reduction in nephrin lev-
els and exacerbation of renal dysfunction in the ApoEKO 
mice associated with enhanced plasma levels of Cr 
and BUN (Table  2; Fig.  6). Intriguingly, treatment with 
rhACE2 rescued Ang II-induced hypertension and renal 
dysfunction in the Ang II-infused ApoEKO mice asso-
ciated with down-regulation of Ang II levels (Table  2; 
Fig.  6). The Ang II-mediated reductions of renal ACE2 
and nephrin levels in the ApoE-mutant mice were sig-
nificantly prevented by rhACE2 supplementation, along 
with an increase in renal Ang-(1-7)/Ang II ratio (Fig. 6). 
However, in the vehicle-infused ApoEKO mice, rhACE2 
treatment significantly reduced plasma Cr levels without 
affecting SBP, BUN, Ang II and Ang-(1-7) levels (Table 2). 
Administration of rhACE2 had no effects on circulat-
ing levels of TG and CHO in both the vehicle-infused 
and Ang II-infused ApoEKO mice (Table  2). Consistent 
with worsened renal dysfunction, Ang II infusion in the 
ApoEKO mice exhibited exacerbation of kidney inflam-
mation with enhanced expression of TNF-α, TNFRSF1A, 
IL-1β, IL-6, and IL-17A (Fig. 7). Treatment with rhACE2 
reduced renal levels of TNF-α and TNFRSF1A, but not 
TNFRSF1B, in both the vehicle-infused and Ang II-
infused ApoEKO mice (Fig.  7). Notably, rhACE2 sup-
plementation was effective at suppressing the increased 
expression of IL-1β, IL-6, and IL-17A in the Ang II-
infused ApoEKO mice (Fig. 7). Taken together, these data 
provide some evidence for protective roles of ACE2 in 
the Ang II-mediated renal dysfunction and inflamma-
tion in the ApoEKO mice through normalization of the 
nephrin and TNF-α-TNFRSF1A signaling.
Table 3 Renal protein levels of cytokines and TNF-α-related signaling in the ApoE/ACE2 DKO mice
Gene name Description Folds up‑ or down‑regulation  
(vs. ApoEKO mice)
P value
TNF‑α Tumor necrosis factor 5.16 0.023
CD30 ligand TNFSF8; TNF ligand superfamily member 8 1.92 0.012
CD30 TNFRSF8; TNF receptor superfamily member 8 1.15 0.540
Fas ligand TNFSF6; TNF ligand superfamily member 6 2.74 0.025
TNFRSF1A TNF RI; TNF receptor superfamily member 1A 2.10 0.020
TNFRSF1B TNF RII; TNF receptor superfamily member 1B 1.09 0.665
GITR TNFRSF18; TNF receptor superfamily member 18 2.28 0.026
OGN Osteoprotegerin; TNF receptor superfamily member 11B 2.27 0.024
TRANCE TNFSF11;TNF ligand superfamily member 11 2.15 0.023
TROY TNFRSF19; TNF receptor superfamily member 19 1.19 0.456
RENTES CCL5; C–C motif chemokine 5 2.33 0.006
ICAM‑1 Intercellular adhesion molecule 1 1.79 0.014
VCAM‑1 Vascular cell adhesion protein 1 1.14 0.730
IL‑1α Interleukin‑1 alpha 1.47 0.205
IL‑1β Interleukin‑1 beta 2.69 0.025
IL‑2 Interleukin‑2 1.80 0.101
IL‑3 Interleukin‑3 2.34 0.034
IL‑4 Interleukin‑4 −1.74 0.024
IL‑5 Interleukin‑5 1.41 0.567
IL‑6 Interleukin‑6 2.61 0.033
IL‑7 Interleukin‑7 1.37 0.293
IL‑9 Interleukin‑9 1.62 0.220
IL‑10 Interleukin‑10 −1.19 0.065
IL‑2p40/p70 Interleukin‑12 subunit beta 1.71 0.154
IL‑12 p70 Interleukin‑12 subunit alpha 1.20 0.539
IL‑13 Interleukin‑13 2.43 0.023
IL‑15 Interleukin‑15 1.38 0.183
IL‑17A Interleukin‑17A 3.11 0.010
IL‑17RB Interleukin‑17 receptor B 1.22 0.301
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ACE2 is a negative regulator in kidney superoxide 
generation and adverse renal injury in the ApoE‑deficient 
mice
We next examined the influences of rhACE2 treatment 
on renal oxidative stress levels and glomerulus ultras-
tructure changes in the ApoEKO mice. Ang II infusion 
resulted in a predictable increase in renal ROS produc-
tion in the ApoEKO mice as assessed by DHE stain-
ing (Fig.  8c, d). Importantly, Ang II-induced increases 
in superoxide generation in the ApoEKO kidneys were 
largely rescued by rhACE2 treatment (Fig. 8c) because of 
prevention of the Ang II-mediated activation of NADPH 
oxidase (Fig. 8c) and expression of NOX4 (Fig. 8b), with 
no change in NOX2 levels (Fig.  8a). The superoxide 
scavengers, polyethylene glycol-superoxide dismutase 
(650  U/ml) and diphenylene iodonium (10  μmol/l) 
(Fig. 8), were used to confirm the Ang II-mediated ROS 
production in the ApoEKO kidneys. Consistent with 
exacerbation in renal inflammation and oxidative stress, 
renal glomerulus ultrastructure injury was aggravated in 
the ApoE/ACE2 DKO mice or Ang II-infused ApoEKO 
mice when compared with the ApoEKO control mice 
(Fig. 9). These ultrastructure changes were characterized 
with renal mesangial cell necrosis, podocyte depletion 
Fig. 4 ACE2 deficiency led to increases in renal inflammation in the ApoE/ACE2 DKO mice. The real‑time PCR (a–f) and Western blot analyses (g–j) 
revealed the mRNA or protein levels of the inflammatory cytokines in mice kidneys, including TNFα, TNFRSF1A, TNFRSF1B, IL‑1β, IL‑6, and IL‑17A. 
n = 5–6. GAPDH or β‑actin was used as an endogenous control. RE relative expression, WTC wild‑type control, ApoE apolipoprotein E, KO knockout, 
DKO the ApoE/ACE2 double knockout, TNFα tumor necrosis factor‑α, IL interleukin. Please see other abbreviations in Table 3. *P < 0.05; **P < 0.01 
compared with WT control group; #P < 0.05 compared with ApoEKO group.
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from the glomerular wall, the foot process effacement 
and the thickening glomerular capillary basement mem-
brane (Fig. 9), contributing to progression of kidney dam-
age. Notably, there were immune complexs, another key 
determinant of adverse renal injury, in glomerulus of 
kidneys in both the ApoE/ACE2 DKO mice and Ang II-
infused ApoEKO mice (Fig.  9). In response to rhACE2 
treatment, renal ultrastructure injury was alleviated in 
the Ang II-infused ApoEKO mice (Fig.  9). ACE2 serves 
as a negative regulator of Ang II-mediated abnormal 
nephrin signaling, inflammation and oxidative stress in 
the kidneys, ultimately contributing to attenuation of 
kidney dysfunction and improvement of adverse renal 
injury in the ApoEKO mice (Fig. 10).
Discussion
The present study uncovered the insights into the 
involvement of ACE2 deficiency in the development of 
kidney inflammation, oxidative stress and adverse renal 
injury in the atherosclerosis-prone ApoEKO mice. To 
our knowledge, this is the first report of the relation-
ship between nephrin signaling and kidney injury in the 
absence of ApoE and ACE2 status. Importantly, recom-
binant human ACE2 treatment was able to rescue Ang 
II-mediated pathological actions in the ApoEKO mice 
with improvement of renal inflammation, oxidative stress 
and ultrastructure injury. ACE2 has local physiologi-
cal effects, especially in the kidney, turning the balance 
within the RAS cascade from pro-inflammatory and pro-
oxidant effects to anti-inflammatory and anti-oxidant 
effects [23–25]. Our data showed that downregulation 
of renal ACE2 levels was observed in the ApoEKO mice 
with no changes in SBP and renal Ang II levels. Genetic 
ACE2 deletion resulted in significant increases in SBP 
levels and superoxide production and exacerbation of 
renal dysfunction in the ACE2KO and ApoE/ACE2 
double KO mice. However, deficiency of ACE2 had no 
effect on circulating lipid levels in both the ACE2KO and 
ApoE/ACE2 double KO mice. Consistent with reports 
from other groups [7, 11], our findings implicated that 
loss of ACE2 was linked with elevated Ang II levels and 
augmented expression of pro-inflammatory cytokines/
chemokines, including TNF-α, IL-1β, and IL-6. These 
changes were associated with a downregulation of renal 
Fig. 5 ACE2 deficiency resulted in increases in oxidative stress levels in the ApoE/ACE2 DKO kidneys. a, b The real‑time PCR analysis revealed 
mRNA expression of the NADPH oxidase subunits NOX2 (a) and NOX4 (b) in mice kidneys (n = 6). GAPDH was used as an endogenous control. 
c, d Representative dihydroethidium fluorescence images (c), relative fluorescence values and lucigenin‑enhanced chemiluminescence assay 
(d) exhibited the superoxide generation and NADPH oxidase activity in mice kidneys. n = 5. WTC wild‑type control, ApoE apolipoprotein E, ACE2 
angiotensin‑converting enzyme 2, KO knockout, DKO the ApoE/ACE2 double knockout. *P < 0.05; **P < 0.01 compared with WT control group; 
#P < 0.05 compared with ApoEKO group.
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nephrin levels and a marked increase in plasma BUN and 
Cr levels in the ApoE/ACE2 double KO mice. Interest-
ingly, an obvious elevation in IL-17A levels was observed 
in the ApoEKO kidney, and ACE2 deficiency or Ang II 
infusion further increased the renal levels of IL-17A in 
the ApoEKO status. IL-17A is involved in many inflam-
matory processes by promoting Ang II-mediated hyper-
tension and vascular dysfunction, both of which are risk 
factors for atherosclerosis [26]. Deletion of IL-17A has 
been shown to reduce inflammation and increase nitric 
oxide (NO) levels in the ApoE/IL-17A DKO mice with no 
alteration in plaque burden [26], implying the contribu-
tion of IL-17A to renal inflammation in the ApoE-mutant 
state or ApoE/ACE2 double mutant state. Our data point 
to ACE2 as an important regulator of renal inflammation 
and a novel target for kidney-protective therapies.
Atherosclerosis is a complex inflammatory disease 
characterized by derangements in the renal, metabolic 
and immune systems, leading to renal inflammation, oxi-
dative stress and the development of CKD [1, 3, 4, 27]. 
The Ang II/AT1 receptor signaling plays a critical role in 
the development of atherosclerosis and renal injury by 
controlling inflammation, oxidative stress and immune 
systems [3, 8, 27]. Our data demonstrated an important 
role of Ang II-induced pro-inflammatory and pro-oxidant 
state in the ApoEKO kidneys and its ability to be modu-
lated by ACE2. We demonstrated that deletion of ACE2 
facilitated renal inflammation and ROS production in 
both the single ACE2-mutant mice and the ApoE/ACE2 
double-mutant mice. These changes were associated with 
enhanced expression of oxidative stress-inducible gene 
NOX4, with no change in NOX2 levels. Conversely, sup-
plementation with rhACE2 dramatically reduced the Ang 
II-mediated oxidative stress in the ApoEKO mice in part 
by preventing the expression of NOX4 and the activity of 
NADPH oxidase. In addition, we found that the ApoE-
mutant mice lacking ACE2 (ApoE/ACE2 DKO) exhibited 
substantial increases in renal AT1 receptor levels and kid-
ney inflammation as demonstrated by remarkable upreg-
ulations of proinflammatory cytokines TNF-α, IL-1β, 
Fig. 6 Treatment with rhACE2 abolished Ang II‑mediated reduction in renal nephrin expression in ApoEKO mice. a Representative Western blot 
analysis showing ACE2 protein levels in the mice kidneys. b, c The Ang II and Ang‑(1‑7) levels (b) and the ratio of Ang‑(1‑7)/Ang II (c) in the kidney 
cortex of the ApoEKO mice treated with Ang II and/or human recombinant ACE2 (rhACE2). d, e The real‑time PCR (d) and Western blotting analyses 
(e) exhibited levels of nephrin in mice kidneys. β‑actin or GAPDH was used as an endogenous control. n = 5–6; RE relative expression, AU arbitrary 
units; **P < 0.01 compared with ApoEKO control group; #P < 0.05; ##P < 0.01 compared with ApoEKO + Ang II group.
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IL-6, RANTES, ICAM-1 and TNF-α related signaling 
such as TNFSF6, TNFRSF18, TNFRSF11B, TNFSF11 and 
TNFRSF1A. Within the inflammatory response, the Ang 
II/AT1 receptor-induced TNF-α signaling can control the 
generation of anti-inflammatory cytokine NO and poten-
tiate renal expression of pro-inflammatory cytokines IL-1 
and IL-6 through the activation of nuclear factor-κB (NF-
κB) signaling, thereby functioning as a major regulator 
of inflammation and kidney damage [27, 28]. Treating 
ACE2-mutant mice with TNF-α triggered upregulated 
expression of inflammatory factor NF-κB [7]. In turn, 
the activation of NF-κB signaling is an active source of 
Fig. 7 Treatment with rhACE2 prevented Ang II‑mediated renal inflammation in the ApoEKO mice. The real‑time PCR (a–f) and Western blot analy‑
ses (g–i) demonstrated the renal mRNA or protein expression of inflammatory cytokines in the ApoEKO mice, including TNFα, TNFRSF1A, TNFRSF1B, 
IL‑1β, IL‑6, and IL‑17A (n = 4–6). GAPDH or β‑actin was used as an endogenous control. RE relative expression, rhACE2 human recombinant ACE2, 
Ang II angiotensin II. Please see other abbreviations in Table 3. *P < 0.05; **P < 0.01 compared with ApoEKO control group; #P < 0.05; ##P < 0.01 
compared with ApoEKO + Ang II group.
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pro-inflammatory cytokine TNF-α, further amplify-
ing proinflammatory effects of the Ang II/AT1 recep-
tor. NF-κB plays an important role in the Ang II/AT1 
receptor-mediated TNF-α signaling, renal inflamma-
tion, and progression of renal disease [29, 30]. Deletion 
of ACE2 promoted the Ang II/AT1 receptor-stimulated 
NF-κB-dependent renal inflammation such as upregula-
tion of TNF-α, IL-1β and increased macrophage and T 
cell infiltration in the kidneys, which were linked with 
an increase in the levels of phospho-IκBα and phospho-
NF-κB/p65 and degradation of IκBα and NF-κB/p65, 
indicating the interaction between the NF-κB activa-
tion and the AT1 receptor-mediated TNF-α signaling 
[30]. Notably, TNF-α-deficient mice had blunted Ang 
II-induced hypertensive responses and reduced kidney 
damage in the model of Ang II-mediated kidney dis-
ease [27], confirming a role for kidney-derived TNF-α 
to promote Ang II/AT1 receptor-induced renal injury. 
The effects of TNF-α are initiated by engagement of two 
distinct TNF receptors, TNFRSF1A and TNFRSF1B [31, 
32]. Engagement of TNFRSF1A is primarily thought 
to be responsible for the deleterious effects of TNF-
α, whereas TNFRSF1B activation mediates protective 
mechanisms [31, 32]. Thus, the net effects of TNF-α on 
kidney injury in the ApoEKO mice may depend on the 
relative contribution of TNFRSF1A and TNFRSF1B sign-
aling. As shown in this study, ACE2 deficiency triggers 
a marked increase in expression of pro-inflammatory 
factors in the ApoEKO kidneys, including TNF-α, and 
TNFRSF1A, without affecting the TNFRSF1B expression. 
ACE2 showed antiinflammatory properties by preventing 
expression of inflammatory cytokines [16, 24, 25] while 
selective inhibition of ACE2 resulted in a proinflamma-
tory phenotype [11, 15, 25]. In this work, we observed 
Fig. 8 Effects of rhACE2 on renal oxidative stress levels in the Ang II‑infused ApoEKO mice. a, b The real‑time PCR analysis revealed mRNA expres‑
sion of the NADPH oxidase subunits NOX2 (a) and NOX4 (b) in mice kidneys (n = 4–6). GAPDH was used as an endogenous control. c–e Represent‑
ative dihydroethidium fluorescence images (c), relative fluorescence values (d) and lucigenin‑enhanced chemiluminescence assay (e) exhibited the 
superoxide generation and NADPH oxidase activity in mice kidneys. n = 4–5. AU arbitrary units, ApoE apolipoprotein E, ACE2 angiotensin‑converting 
enzyme 2, KO knockout, rhACE2 human recombinant ACE2, Ang II angiotensin II, PEG-SOD polyethylene glycol‑conjugated superoxide dismutase, 
DPI diphenylene iodonium chloride (NADPH oxidase inhibitor). *P < 0.05; **P < 0.01 compared with the ApoEKO control group; ##P < 0.01, com‑
pared with the ApoEKO + Ang II group.
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that treatment with rhACE2 significantly blunted Ang II-
mediated impairment of kidney function and enhanced 
renal inflammatory cytokines levels of IL-1β, IL-6, IL-
17A in the ApoEKO mice with suppression of the TNF-
α-TNFRSF1A signaling. Our findings indicated beneficial 
roles of ACE2 in the inflammatory response and kid-
ney dysfunction, at least in part, through inhibition of 
the TNF-α-TNFRSF1A signaling pathway. However, 
we could not elucidate the extent to which TNF recep-
tor activation affects renal inflammation and dysfunc-
tion in the absence of ApoE and ACE2 status. Additional 
researches are required to clarify this issue.
Another significant finding in the current study was the 
identification that downregulation of renal nephrin lev-
els and enhanced expression of AT1 receptor were key 
mechanisms by which loss of ACE2 promoted progres-
sive renal injury and dysfunction in the ApoE/ACE2 DKO 
mice. In this work, we found that genetic ACE2 deletion 
resulted in declined expression of nephrin and aug-
mented levels of Ang II and AT1 receptor in the kidneys 
of the ApoE/ACE2 double-mutant mice, contributing to 
the exacerbation of kidney dysfunction and adverse renal 
injury. Ang II-mediated renal injury has been shown to 
be induced by abnormal expression and distribution of 
nephrin in kidney [12, 33–35]. Furthermore, Ang II facili-
tates renal injury through downregulation of nephrin and 
promotes podocyte injury indirectly by inducing cellu-
lar hypertrophy and alterations in the anionic charge of 
the glomerular basement membrane in the kidney [34, 
35]. It is well established that nephrin is required dur-
ing kidney development for the maturation of podocytes 
and formation of the slit diaphragm junctional complex 
[33–35]. Nephrin deficiency is considered a pathologic 
feature of glomerular injury [33, 35], and nephrin-mutant 
mice develops more exaggerated glomerular enlarge-
ment and increased apoptosis with mild proteinuria, 
Fig. 9 Renal ultrastructure changes in mice. The renal glomerulus ultrastructural changes were observed in kidneys of mice by transmission elec‑
tron microscope analysis (a–g ×4200 magnification; h–k ×7400 magnification). Compared with the ApoEKO mice, renal ultrastructure injury was 
aggravated in the ApoE/ACE2 DKO mice or the Ang II‑infused ApoEKO mice. These ultrastructure changes were characterized with renal mesangial 
cell necrosis (green star), the immune‑complex (IC) formation, podocyte depletion from the glomerular wall linked with the foot process effacement 
(red arrow) and the thickening and stiffening glomerular capillary basement membrane (red triangle). WTC wild‑type control, ApoE apolipoprotein E, 
ACE2 angiotensin‑converting enzyme 2, KO knockout, DKO double knockout, rhACE2 human recombinant ACE2, Ang II angiotensin II, IC immune‑
complex.
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foot process effacement, mesangial hypercellularity and 
sclerosis, and glomerular basement membrane thicken-
ing [35]. Consistent with reduction of nephrin levels and 
exacerbation in renal dysfunction, as shown in this study, 
renal glomerulus ultrastructure injury was aggravated in 
both the ApoE/ACE2 DKO mice and the Ang II-treated 
ApoEKO mice. These changes were characterized with 
renal mesangial cell necrosis, immune complexs forma-
tion, glomerular podocyte depletion, foot process efface-
ment and the thickening glomerular capillary basement 
membrane. Notably, rhACE2 treatment was able to res-
cue Ang II-induced kidney dysfunction and adverse renal 
injury in the ApoEKO mice, in association with upregu-
lated expression of ACE2 and nephrin. This is in agree-
ment with previous reports demonstrating that blockade 
of the RAS ameliorates kidney injury in mice by enhanc-
ing levels of nephrin and preventing damage of kidney 
[35]. These data underscore renoprotective effects of 
ACE2 with the anti-inflammatory properties via modula-
tion of the nephrin and TNF-α-TNFRSF1A signaling.
Clinical trial evidence indicates that the blockade of 
the RAS by ACE inhibitors or AT1 receptor blockers (ARB) 
has been shown to alleviate renal injury, improve renal func-
tion and reduce renal events in patients with chronic kid-
ney diseases and ESRD [2, 5, 6, 29, 34]. ACE2 is an essential 
regulator in maintaining the balance between Ang II gen-
eration and Ang II degradation locally within the kidney 
regardless of systemic disease conditions [7, 8, 36]. In this 
work, downregulation of renal ACE2 protein was observed 
in the Ang II-infused ApoEKO mice with elevated Ang II 
levels in both plasma and kidney. Intriguingly, treatment 
with ACE inhibitors or ARB increases ACE2 expression and 
Ang-(1-7) levels in the kidney and cardiovascular system [9, 
37, 38]. As such, enhancing ACE2 actions such as rhACE2 
has emerged as a potential therapeutic strategy, function-
ing as an endogenous ACE inhibitor or natural ARB [36, 
38–41]. Our present work and previous studies [9, 36, 38] 
have obviously exhibited downregulation of Ang II levels 
and upregulation of Ang-(1-7) levels in response to rhACE2 
and are consistent with in  vivo effects in healthy human 
volunteers whereby rhACE2 treatment lowered Ang II lev-
els and augmented Ang-(1-7) levels [40] and in vitro effects 
of rhACE2 which degrades plasma Ang II into Ang-(1-7) 
[41]. In a murine model of Ang II-mediated cardiorenal 
injury, blocking Ang-(1-7) action by A779 remarkably pre-
vented the cardiorenal protective roles of rhACE2, implying 
that the therapeutic effects of rhACE2 is clearly dependent 
on the action of Ang-(1-7) [36]. In the present work, com-
pared with the ApoEKO control kidneys, the ratio of Ang-
(1-7)/Ang II was observed in the Ang II-infused ApoEKO 
kidneys with no changes of Ang-(1-7) levels. Treatment of 
rhACE2 strikingly promoted renal Ang-(1-7)/Ang II ratio in 
the Ang II-infused ApoEKO mice. Our data implied that the 
increases in ACE2 protein and the ratio of Ang-(1-7)/Ang 
II mediated by rhACE2 treatment were responsible for the 
improvement of kidney dysfunction and the attenuation of 
adverse renal injury in the ApoE-null mice in response to 
Ang II. Thus, the development of novel strategies to inter-
fere with ACE2/Ang-(1-7) might be a promising field for the 
therapeutic approach in atherosclerosis and kidney diseases.
Conclusions
In summary, genetic ACE2 deletion resulted in greater 
increases in renal inflammation, superoxide generation 
and exacerbation of kidney dysfunction in an ApoE-defi-
cient state with downregulation of nephrin signaling and 
elevation of NOX4 levels. In contrast, rhACE2 treatment 
appeared to show counter regulation against Ang II-
mediated kidney inflammation, oxidative stress and renal 
injury by augmenting renal Ang-(1-7) levels, enhanc-
ing nephrin expression, and preventing the activation 
of NOX4 and TNF-α-TNFRSF1A signaling and these 
mechanisms may be involved in the therapeutic benefits 
of ACE2 in the ApoE-deficient mice. Our data suggest 
that ACE2 is a key negative modulator of atherosclerosis-
related kidney inflammation, oxidative stress and adverse 
renal injury, and targeting the ACE2/Ang-(1-7) signaling 
has potential therapeutic importance for preventing and 
Fig. 10 Effects and potential mechanisms of ACE2 on renal inflam‑
mation and injury in ApoE‑deficient mice. ACE2 serves as a key 
regulator of Ang II‑mediated actions in kidneys. On one hand, ACE2 
deficiency results in downregulation of nephrin levels and greater 
increases in ROS production and expression of proinflammatory 
cytokines TNFα, IL‑1, IL‑6, and IL‑17A, contributing to renal inflamma‑
tion, oxidative stress and structural injury in the ApoEKO mice. On the 
other hand, rhACE2 treatment promotes nephrin levels and amelio‑
rates the Ang II‑induced kidney inflammation and ROS generation, 
functioning as a negative regulator for kidney dysfunction and renal 
injury in the ApoEKO mice.
Page 15 of 16Jin et al. J Transl Med  (2015) 13:255 
treating atherosclerotic renal injury and kidney diseases. 
In the future, it will be important to evaluate the exact 
mechanisms and antiatherogenic, and antiinflammatory 
responses to interventions aimed at amplifying ACE2 
action directly. Future clinical studies in atherosclerosis 
and chronic kidney diseases are required to more pre-
cisely clarify the role of ACE2 or nephrin as a biomarker 
of atherosclerosis-related kidney injury.
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